Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tandem Diabetes Care (TNDM)

Tandem Diabetes Care Q2 sales rise 13% to $221.9 million; raises 2024 sales guidance

Positive Impact 4 of 5 earnings Written later

Tandem Diabetes Care reported second-quarter 2024 GAAP sales up 13% to $221.9 million and a narrower GAAP net loss of $30.8 million, compared with $35.8 million a year earlier. The company also raised its full-year 2024 non-GAAP sales estimate to approximately $885 million to $892 million, which it attributes to recent product launches and customer retention. The company still reported a loss, and its Tandem Choice program adds accounting complexity to GAAP comparisons.

Key points

  • Q2 2024 GAAP sales were $221.9 million, up 13% from $195.9 million in Q2 2023; non-GAAP sales were $221.8 million, up 12%.
  • GAAP net loss was $30.8 million, or $0.47 per share, versus $35.8 million, or $0.55 per share, in Q2 2023.
  • Full-year 2024 non-GAAP sales are now estimated at approximately $885 million to $892 million, with third-quarter sales of $222 million to $225 million.
  • Non-GAAP gross margin is estimated at approximately 51% for the full year, and Adjusted EBITDA margin at breakeven.

The filing

CompanyTandem Diabetes Care (TNDM)
Form8-K, current report
Filed with the SECAug 1, 2024, 4:07 PM ET
Accession number0001438133-24-000176

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 01, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.